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Abstract
Background: The frequency of Taenia solium, a zoonotic helminth, is increasing in many countries of sub-Saharan
Africa, where the prevalence of the human immunodeficiency virus (HIV) is also high. However, little is known
about how these two infections interact. The aim of this study was to compare the proportion of HIV positive (+)
and negative (−) individuals who are infected with Taenia solium (TSOL) and who present with clinical and
neurological manifestations of cysticercosis (CC).
Methods: In northern Tanzania, 170 HIV+ individuals and 170 HIV– controls matched for gender, age and village of
origin were recruited. HIV staging and serological tests for TSOL antibodies (Ab) and antigen (Ag) were performed.
Neurocysticercosis (NCC) was determined by computed tomography (CT) using standard diagnostic criteria.
Neurological manifestations were confirmed by a standard neurological examination. In addition, demographic,
clinical and neuroimaging data were collected. Further, CD4+ cell counts as well as information on highly active
antiretroviral treatment (HAART) were noted.
Results: No significant differences between HIV+ and HIV– individuals regarding the sero-prevalence of
taeniosis-Ab (0.6% vs 1.2%), CC-Ab (2.4% vs 2.4%) and CC-Ag (0.6% vs 0.0%) were detected. A total of six NCC cases
(3 HIV+ and 3 HIV–) were detected in the group of matched participants. Two individuals (1 HIV+ and 1 HIV–) presented
with headaches as the main symptom for NCC, and four with asymptomatic NCC. Among the HIV+ group, TSOL was
not associated with CD4+ cell counts, HAART duration or HIV stage.
Conclusions: This study found lower prevalence of taeniosis, CC and NCC than had been reported in the region to date.
This low level of infection may have resulted in an inability to find cross-sectional associations between HIV status and
TSOL infection or NCC. Larger sample sizes will be required in future studies conducted in that area to conclude if HIV
influences the way NCC manifests itself.
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Background
Taenia solium is a zoonotic parasite which has consider-
able impact on human and animal health as well as on
the agricultural and health sectors in many low income
countries [1]. In humans, the adult stage of the tape-
worm is found in the intestines (taeniosis) and the larval
stage can develop as cysticerci mainly in the subcutane-
ous tissue, skeletal and heart muscles (cysticercosis, CC),
and of most concern for public health, in the brain
(neurocysticercosis, NCC) [2–4].
NCC is believed to be the most common helminthic
infection of the central nervous system (CNS) worldwide
and is well known as a major cause of acquired epilepsy
or epileptic seizures resulting in reduced quality of life,
social stigma, and high care costs for affected individuals
and their caretakers [5–7]. In areas where the infection
is endemic, it is estimated that 30% of people with
epilepsy (PWE) show lesions of NCC in their brain [8].
In a hospital-based cross-sectional study conducted in
northern Tanzania in 2006, definitive and probable NCC
(as classified by Del Brutto et al.) was found in 2.4 and
11.3% of PWE, respectively [9, 10]. In Zambia, in a
cross-sectional community-based study among PWE,
4.1% could be revealed as definitive NCC and 24.5% as
suggestive NCC. In the same study, 2.5 and 0.0% of con-
trols in the non-PWE group were defined as definite and
suggestive NCC [11]. Besides epilepsy, other clinical
manifestations such as acute and chronic headaches,
signs or symptoms of intracranial hypertension, neuro-
psychiatric disorders and focal neurological deficits have
been described [6, 12].
Human infection by the adult tapeworm - T. solium
taeniosis - causes only mild symptoms, such as abdom-
inal pain or diarrhoea, if any [13]. Data on taeniosis
prevalence in sub-Saharan Africa are still scarce. Cross-
sectional studies conducted in rural communities have
reported prevalence proportions of taeniosis using a copro-
antigen-enzyme linked immunosorbent assay (copro-
Ag-ELISA) of 19.9% in western Kenya, 6.3 to 11.9% in the
Eastern Province of Zambia, and 1.1 to 5. 2% in Tanzania
[14–18]. Moreover, a Tanzanian study conducted in
Mbeya Rural District reported a taeniosis-antibody (Ab)
prevalence of 4.1% using a rES38-immunoblot [17].
Many T. solium endemic areas in sub-Saharan Africa
are also endemic for the human immunodeficiency virus
(HIV) [19]. Nearly 25 million people are estimated to
live with HIV/acquired immunodeficiency syndrome
(AIDS) in sub-Saharan Africa [20]. While an overall
decline in HIV/AIDS prevalence is observed in most
African countries, the incidence of HIV is increasing in
some rural areas [21] - most of them resource-poor -
where T. solium has also been reported [12, 19]. This
suggests the presence of co-infections in several pre-
disposed countries. However, while HIV has been shown
to interact with tuberculosis, malaria and some soil-
transmitted parasitic infections [22–24], much less is
known about how HIV modifies the manifestations of
NCC. Not only may HIV modify clinical manifestations,
but it may also impact the interpretation of sero-diagnostic
results and required treatment schemes for NCC and tae-
niosis [25, 26]. Some authors have suggested that patients
with higher CD4+ T-lymphocyte (CD4+) counts are more
likely to develop symptomatic NCC needing treatment,
whereas patients with advanced HIV and lower CD4+
counts present either asymptomatically or atypically (giant
and racemose cysts) [27–30]. In contrast, in a cross-
sectional study conducted among HIV+ people in
Mozambique, no significant correlation was found between
presence of CC-Ab and CD4+ counts [31]. The hypotheses
that HIV+ individuals with low CD4+ counts are more
likely to develop symptomatic NCC was not supported in
another study [32]. A Mexican autopsy study showed that
NCC was even less common in people with HIV (1.1%)
than among people without HIV (2.4%) [33], whereas in
South-Africa, NCC has been described as one of the most
present focal brain lesions in people with HIV/AIDS pre-
senting with neurological signs [30]. In addition to seem-
ingly unpredictable NCC manifestations in people with
HIV/AIDS, highly active antiretroviral therapy (HAART)
may lead to activation of latent NCC in the context of an
immune reconstitution inflammatory syndrome with poten-
tially deleterious effects for the affected individual [32, 34].
Based on the above controversy, the aim of this study
was to estimate the prevalence of and factors associated
with T. solium infections (taeniosis, CC, and NCC) among
HIV+ and HIV– individuals in northern Tanzania.
Methods
Study sites
HIV positive (HIV+) individuals were recruited at the HIV
Care and Treatment Centre (CTC) of HLH in Haydom,
Mbulu district, Manyara region, northern Tanzania. HLH
is a 429 bed-hospital serving around 15 400 inpatients and
70 150 outpatients per year [35]. As of December 2012, 1
898 HIV patients had sought care at the CTC clinic. All
HIV/AIDS-related investigations and treatment are free of
charge to the patient according to the Tanzanian National
Policy on HIV/AIDS care and treatment. The villages of
residence of the HIV+ patients were used to sample match
HIV– individuals. These villages were located in the
Mbulu, Hanang and Babati districts of the Manyara region
and Iramba district of the Singida region (Fig. 1). All study
districts were characterized by poor infrastructure and
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living conditions, lack of sanitation, and farming as the
main source of income. In 2008, the Manyara region re-
ported that 19.6% of rural households reared pigs with the
largest number of pigs found in the Mbulu district (51 198
pigs, 53.1% of the pig population in the Manyara region),
followed by the Babati district (19 587 pigs, 20.3%) and
the Hanang district (15 310 pigs, 5.9%) [36]. The Iramba
district reported 42 073 pigs, which corresponds to 86% of
the total pig population in the Singida region [37].
According to the Tanzania HIV/AIDS and Malaria
Indicator Survey (THMIS) 2011-12 [38], the overall HIV
prevalence in Tanzania was estimated to be 5.1% among
adults aged 15–49 years (6% among women, 4% among
men) during our study period. In the same report, preva-
lence proportions of 1.5% for the Manyara region and
3.3% for the Singida region were estimated. It is believed
that HIV emerged in these regions relatively late (mid
1990s), but has steadily increased ever since and already
reached the country’s average in some districts like
Babati [39].
Study design and study population
A cross-sectional study was conducted among 170 HIV+
and 170 age (+/− 10 years), gender and village of
residence-matched HIV– individuals. The rationale for
matching was to limit variation in exposure to T. solium
eggs among HIV+ and HIV– participants. Participants
were recruited from January 2011 to February 2013.
Every day, HIV+ patients attending CTC for regular
clinical check-ups and/or HAART were invited to par-
ticipate in the study. Age, gender and village of residence
of each consenting HIV+ patient were entered into an
Excel sheet on a daily basis. For the age range of the
individual matching partner a range of +/− 10% (with
minimum and maximum target age) was calculated.
Following this list, a field team including one nurse from
CTC and one research assistant went each day to the
appropriate villages to identify matching HIV– partici-
pants. With the help of village headmen/headwomen
and local helpers, potential candidates were visited at
their homes and asked to voluntarily participate in this
study. The overall recruitment was stopped when a total
of 433 participants, resulting in 170 matching pairs, had
been identified (Fig. 2). Initial HIV testing of individuals
enrolled in CTC was performed using two rapid Ab-tests
according to the Tanzanian national algorithm for HIV test-
ing: Alere Determine HIV-1/2 (Abbott laboratories, Abbott
Park, IL, USA) and Uni-Gold™ Recombigen® HIV-1/2
(Trinity Biotech, USA). In the case of a positive reading in
the Alere Determine HIV-1/2 test the serum sample
was subjected to the second rapid Ab-test: Uni-Gold™
Recombigen® HIV-1/2 test. Concordant positive results
were interpreted as positive for HIV-Ab. Discordant re-
sults were interpreted as inconclusive and the sample was
sent to the regional hospital for confirmatory test using
two ELISA tests: Enzygnost anti-HIV 1 + 2 Plus ELISA
(Behring, Marburg, Germany) and Well-coenzyme HIV
recombinant ELISA (Murex, Dartford, England). In this
study, HIV– individuals were defined as participants who
tested negative using the Alere Determine HIV-1/2 test
and HIV+ individuals as participants tested positive fol-
lowing the algorithm described above. Clinical staging of
Fig. 1 Map of study area and distribution of identified TSOL+ individuals of the initially recruited study population with known origin and
serology (n = 399)
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HIV/AIDS was performed according to the revised World
Health Organization (WHO) guidelines and HAART
treatment status of all HIV+ was noted [40]. Most HIV+
participants (164 or 96%) were receiving HAART and
none were under epilepsy or anti-inflammatory treatment
at the time of recruitment. For ethical reasons, only indi-
viduals aged at least 9 years old were included in the
study. Pregnant women were excluded from the study.
Consenting individuals were invited to answer a ques-
tionnaire, to undertake a clinical examination and to pro-
vide a blood sample for serological testing for taeniosis and
CC. Neuroimaging was offered to all HIV+ participants
and to only those HIV– participants positive to TSOL ser-
ology for ethical reasons.
Blood sample collection and laboratory testing
After counselling by a specially trained nurse, 10 ml of
whole blood was collected by venipuncture from each
participant. HIV+ and HIV– individuals were informed
about the HIV test results immediately thereafter. CD4+
counts were determined for all HIV+ patients using a
fluorescent activated cell sorter machine (FACScount™,
BD Biosciences, US) at the central laboratory of HLH.
Blood samples from HIV– individuals were transported
in cool boxes to the laboratory and immediately placed
into refrigerators until required for further processing.
Blood from HIV+ individuals was refrigerated in the
HLH central laboratory immediately after drawing. After
1 to 6 h, serum was separated and stored at −20 °C until
Fig. 2 Flow chart of the initially recruited and matched study populations. HIV: human immunodeficiency virus, CT: computed tomography,
CC: cysticercosis, T: taeniosis, NCC: neurocysticercosis, Ab: antibody; Ag: antigen
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serological testing for TSOL was performed. On average,
two vials with 2 ml of serum were obtained from each
individual. Four to twelve months later, samples were
shipped to the CDC in Atlanta, USA, for further ana-
lyses and one safety back up sample remained at the
Parasitology Laboratory of MUHAS to avoid total loss in
case of any damage to the sample during the long
shipment. Two tests were used to detect the presence of
Ab to CC (LLGP-EITB and rT24H-immunoblot), one
test was used to detect the presence of antigen (Ag) to
CC (Ag-ELISA) and one test was used to detect the
presence of Ab to taeniosis (rES33-immunoblot). LLGP-
EITB is an enzyme-linked immunoelectrotransfer blot
that detects CC-specific Ab to any of seven glycopro-
teins [41, 42]. The rT24H-test is an immunoblot method
that detects CC-specific Ab to a T. solium recombinant
Ag [43]. The Ag-ELISA that detects Taenia-Ag in serum
is a monoclonal Ab (B158/B60 Ab) based capture ELISA
and was performed following the modified protocol de-
scribed by Dorny et al. [44]. The rES33-test is an immu-
noblot method that detects adult T. solium specific Ab
using a recombinant protein derived from the excretory-
secretory proteins of the adult tapeworms [45, 46]. Ab to
both of the recombinant peptides, rT24H and rES33,
were assessed in the same test. All test results were
interpreted independently and blinded by two scientists
with many years of experience in reading these T. solium
in-house tests. For quality assurance each positive test
was repeated at least once as well as 15% randomly
selected negative samples.
Definitions
T. solium positive individuals (TSOL+) were defined as
those with a positive result in at least one of the four
serological tests described above while those negative in
all tests were considered T. solium negative (TSOL–).
Positive CC cases were defined as those individuals
positive to the LLGP-EITB, rT24H-immunoblot or Ag-
ELISA test. Taeniosis cases were defined as individuals
positive to the rES33-immunoblot test. NCC cases were
defined following the revised criteria of Del Brutto [10].
Viable cysts (active NCC) were defined as cystic lesions
(with or without visible scolex) or lesions with ring en-
hancement. Calcified cysts (inactive NCC) were defined as
hyperdense lesions with no sign of ring enhancement [47].
Neuroimaging
All HIV+ individuals underwent CT examination at
baseline in a Toshiba Auklet Single Slice Spiral CT
machine at HLH. HIV–/TSOL+ participants received
their CT examination at the Aga Khan Health Centre in
Arusha since the CT machine at HLH did not work at
the time of the follow-up examinations. All follow-up
CT scans of HIV+/TSOL+ were also performed in
Arusha for the same reason. This health center used a
Siemens Somatom Emotion CT machine. Both machines
provided 5 mm slices and took 64 slices per picture.
Intravenous contrast medium was used in all patients.
CT scan images were evaluated by the local radiologists
and sent to the Department of Neurology at the Technical
University Munich (TUM) for a second blinded evaluation
by a neurologist specialized in NCC diagnoses.
Research questionnaire
Each participant was asked to answer a socio-
demographic and a medical history interview question-
naire. Interviews with HIV+ individuals were performed
by a clinical officer at the CTC clinic and with HIV–
individuals by a trained nurse in their villages of residence.
The study nurses delivered the questionnaires at the CTC
clinic. The questionnaire was adapted from a previous vali-
dated questionnaire used by the Cysticercosis Working
Group in Eastern and Southern Africa (CWGESA) and ad-
dressed socio-demography, pork consumption habits as
well as hygiene and sanitary practices [48]. Questions with
an emphasis on self-reported past and present neurological
disorders, such as acute and chronic headaches, peripheral
nervous system (PNS) and CNS signs and symptoms
including epileptic seizures as well as psychiatric disorders
were included; so were questions on family history of
neurological disease. HIV+ individuals were also asked
about their past HIV history including opportunistic infec-
tions, HAART duration as well as compliance, amongst
others. The questionnaire was developed in English, trans-
lated into Swahili and back-translated to English by two in-
dependent people. A standard neurological examination
was performed on all HIV+ individuals by a medical doctor
specializing in neurology.
Follow-up of seropositive individuals
Ten to fourteen months elapsed between sampling and re-
ceipt of the serological tests results due to logistical
reasons and challenges in tracing patients, therefore
HIV+/TSOL+ participants were invited for a second CT
scan and blood collection (10 ml from each individual) so
that appropriate treatment could be provided. This second
clinical examination and follow-up CT scan were per-
formed shortly before treatment and blood samples were
taken at HLH. Participants identified HIV–/TSOL+ were
invited for their first CT scan and neurological examin-
ation, and second blood drawing before treatment.
Taeniosis positive participants were treated with niclosa-
mide and symptomatic NCC cases with albendazole and
dexamethasone. Present CD4+ counts of HIV+ individuals
were obtained and all serum samples were again shipped
to the CDC in Atlanta for testing as described above. In
addition, before treatment, TSOL+ participants were
asked to provide three stool samples for copro-Ag-ELISA
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testing at the CDC, following a protocol described by
Guezala et al. [49]. Due to financial limitations in our
study copro-Ag testing could only be performed during
follow-up.
Statistical analysis
Analysis of associations between potential risk factors
including HIV (independent variables) and TSOL
(dependent variable) was performed by bivariate ap-
proximative tests (χ2-tests) and exact tests (Fisher’s tests)
using Epi Info, version 3.3.2 (CDC, Atlanta, GA). Signifi-
cant differences were defined as p-values below 0.05.
McNemar tests were used for the paired analysis associ-
ations between the HIV status and TSOL, as well as for
determining all the neurological outcomes. Matched
prevalence proportion ratios (mPPR) and their 95%CI
were obtained using the csmatch command in Stata
14.0. Statistical significance of associations between HIV
and other factors among all matched and unmatched
recruited participants and among the HIV positive group
were evaluated using the chi-square test for categorical
variables and the Kruskal Wallis tests for continuous
variables. Matched analyses were performed using
Stata 14.0.
Results
Demographic characteristics of HIV+ and HIV– individuals
of the matched study population
Initially, 217 HIV+ individuals at CTC and 216 HIV–
individuals were recruited to participate in the study.
The initial aim of this recruitment was to identify a
minimum of 150 matched pairs of HIV+ and HIV–
individuals. After the initial recruitment, 40 HIV+ and
three HIV– individuals were excluded due to a loss of
follow-up or because the individual refused to participate
further in the study. Full data sets comprised a completed
questionnaire, serological results as well as at least one
cranial CT examination and, for HIV+ participants, a
neurological examination. After applying the matching
criteria, seven additional HIV+ individuals and 43 HIV–
individuals were excluded from the group of 177 HIV+
and 213 HIV– individuals, resulting in 170 matching
HIV+/HIV– pairs available for analysis (Fig. 2).
The socio-demographic characteristics of the matched
groups are reported in Table 1. As determined by the de-
sign, each group was 50% male and the median age was
39 years and 40 years in the HIV+ and HIV– matched
participants groups, respectively. The most frequent
tribe was Iraqw (42.6%), followed by Nyiramba (35.6%),
Nyisanzu (8.5%) and other tribes (13.2%). Most of study
participants lived in the Iramba district (45.6%), followed
by the Mbulu (38.5%), Hanang (10.9%) and Babati dis-
tricts (5.0%) (Table 1).
HIV related characteristics
At the time of recruitment 161 of 170 HIV+ individuals
were on regular HAART therapy, three had discontinued
treatment during recent years at least once, and six
had not yet started HAART. The most commonly
used HAART drugs were the first-line combinations
lamivudine/zidovudine or lamivudine/stavudine/nevirapine
(76.5%). 46 (27.1%) HIV+ patients reported opportunis-
tic infections in the past year, mostly pulmonary
Table 1 Demographic characteristics of HIV+ and HIV– individuals
of the matched study population
Variables HIV+ (170) HIV– (170) Total (340) p-value
n % n % n %
Gender 1.00a
Male 85 50.0 85 50.0 170 50.0 –
Age group 0.50*
9–19 years 5 2.9 6 3.5 11 3.2 0.61*
20–39 years 70 41.2 82 48.2 152 44.7 0.23*
40–59 years 83 48.8 72 42.4 155 45.6 0.12*
60–74 years 12 7.1 10 5.9 22 6.5 0.88*
District 0.96*
Mbulu 62 36.5 69 40.6 131 38.5 0.44*
Iramba 82 48.2 73 42.9 155 45.6 0.33*
Hanang 18 10.6 19 11.2 37 10.9 0.86*
Babati 8 4.7 9 5.3 17 5.0 0.80*
Tribe 0.30
Iraqw 66 38.8 79 46.5 145 42.6 0.15
Nyiramba 64 37.6 57 33.5 121 35.6 0.43
Nyisanzu 13 7.6 16 9.4 29 8.5 0.56
Other tribes 27 15.9 18 10.6 45 13.2 0.15
Marital status 0.10
Married 130 76.5 143 84.1 273 80.3 0.08
Single 37 21.8 24 14.1 61 17.9 0.07
Divorced 3 1.8 3 1.8 6 1.8 1.00
Education 0.01
School not attended 37 21.8 18 10.6 55 16.2 –
School attended 133 78.2 152 89.4 285 83.8 –
Occupation 0.02
Peasant 149 87.6 155 91.2 304 89.4 0.53
Housewife 6 3.5 0 0.0 6 1.8 0.01
Business man/woman 3 1.8 0 0.0 3 0.9 0.08
Medical occupation 1 0.6 5 2.9 6 1.8 0.10
Student 6 3.5 1 0.6 7 2.1 0.06
Other 5 2.9 9 5.3 14 4.1 0.28
HIV human immunodeficiency virus
*The factors gender, age group, and district were considered for matching
between HIV+ and HIV–
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tuberculosis and other respiratory diseases as well as
herpes zoster and other infectious skin diseases. The
distribution of HIV/AIDS stages at the time of recruit-
ment was: stage I: 71.8%, stage II: 9.4%, stage III: 16.5%,
and stage IV: 2.4%.
Association between HIV and relevant past medical/
neurological history, current neurological deficits, and
TSOL risk factors among the matched pairs
HIV+ patients had significantly more history of acute head-
aches (mPPR: 2.38; 95%CI: 1.44–3.93) and a past history of
psychiatric disorders (mPPR: 2.50; 95%CI: 1.02–6.15) than
their HIV– counterparts. HIV+ individuals also tended to
have more current overall neurological deficits (mPPR:
7.00; 95%CI: 0.86–56.89) and, specifically, peripheral
neurological deficits (like anesthesia and hypoesthesia of
legs and arms) (mPPR: 2.60; 95%CI: 0.93–7.29), but the
difference was not significant (Tables 2 and 3).
Among the 164 pairs with this information available,
HIV+ participants reported consuming pork significantly
less often than HIV– participants (mPPR: 0.85; 95%CI:
0.75–0.96), but most of those consuming pork reported
to eat pork less than once a month and only properly
cooked. Only 1.2% of all study participants reported ever
seeing cysts in pork. Of all matched study participants,
97.9% reported having access to latrines at home, and
98.2% of those reported always using the latrine. Only
9.4% of the participants reported washing hands before
food consumption; the HIV+ participants tended to
wash their hands less often than the matched HIV–
Table 2 Matched prevalence proportion ratios (mPPR) and their 95%CI for risk factors of TSOL, relevant past medical/neurological
history and current neurological deficits
Factor (total number of pairs
with data available)
Number of pairs mPPR (95%CI)
HIV+ w f/HIV– w f HIV+ w f/HIV– wo f HIV+ wo f/HIV– w f HIV+ wo f/HIV– wo f
History of overall headaches
(162)
8 36 12 114 2.20 (1.39–3.48)
History of acute headaches
(170)
7 31 9 123 2.38 (1.44–3.93)
History of chronic headaches
(170)
0 6 4 160 1.50 (0.42–5.32)
Past or present epileptic
seizures (170)
0 2 1 167 2.00 (0.18–20.06)
Current CNS symptoms (170) 0 7 1 162 7.00 (0.86–56.89)
Current PNS symptoms
(164)
0 7 5 152 2.60 (0.93–7.29)
Any positive test for
TSOL (170)
0 4 4 162 1.00 (0.25–4.00)
Positive for CC-Ag 0 1 0 169 Undefined
Positive for CC-Ab (170) 0 4 4 162 1.00 (0.25–4.00)
Positive for taeniosis-Ab
(168)
0 3 2 163 0.50 (0.05–5.51)
Consumes pork (164) 95 18 38 13 0.85 (0.75–0.96)
Consumes undercooked
pork (170)
0 9 10 151 0.90 (0.37–2.21)
Consumes pork at least
once a month (170)
3 19 20 128 0.76 (0.42–1.38)
Has seen cysts in pigs (170) 0 3 1 166 3.00 (0.31–28.84)
Has access to a latrine (170) 163 2 5 0 0.98 (0.95–1.01)
History of tapeworm carrier
in family (170)
1 6 2 161 2.33 (0.70–7.82)
Handwashing before eating
(170)
0 11 20 139 0.55 (0.26–1.15)
Anthelminthic treatment in
the past year (170)
3 10 20 137 0.57 (0.30–1.05)
mPPR matched prevalence proportion ratio, CI confidence interval, HIV human immunodeficiency virus, w with, wo without, f factor, CNS central nervous system,
PNS peripheral nerval system, TSOL T. solium taeniosis/cysticercosis, CC cysticercosis, Ag antigen
Schmidt et al. Infectious Diseases of Poverty  (2016) 5:111 Page 7 of 15
participants (mPPR: 0.55; 95%CI: 0.26–1.15) (Tables 2
and 3).
There were six pairs where the HIV+ individual re-
ported living in a household with a member with a past
history of tapeworm infection, while the HIV– matched
participant did not; in only two pairs did the HIV–
participant reported such history and the HIV+ did not
(mPPR: 2.33; 95%CI: 0.70–7.82). Fewer HIV+ participants
tended to report anthelminthic treatment in the past than
the matched HIV– participants (mPPR: 0.57; 95%CI:
0.30–1.05), but the difference was not significant (Tables 2
and 3).
Distribution of TSOL tests results among the matched
pairs and in the initially recruited population
There was no association between HIV and TSOL in
this population with four discordant pairs each of
HIV+/TSOL+ with HIV–/TSOL– and HIV+/TSOL– with
HIV–/TSOL+ (mPPR: 1.0; 95%CI: 0.25–4.00). This corre-
sponds to an overall prevalence of 2.4% (95%CI: 0.6–5.9)
of TSOL among both HIV+ and HIV– participants. Com-
paring detailed test results, no significant differences were
observed between matched HIV+ and HIV– individuals
regarding the sero-prevalence of taeniosis-Ab (mPPR: 0.5;
95%CI: 0.05–5.51), CC-Ab (mPPR: 1.0; 95%CI: 0.25–4.00),
and CC-Ag (mPPR undefined because there was only one
discordant pair with HIV+ positive to the Ag-ELISA and
HIV– negative to Ag-ELISA) were detected (Fig. 2,
Tables 2 and 3).
Of the 404 participants initially recruited with sera
available, which include the 340 matched participants,
the prevalence of CC-Ab was 2.5% (95%CI: 1.2–4.5). For
more clinical, serological and risk factor data of those 10
TSOL+ individuals refer to Additional file 2: Table S1.
The prevalence of Ab to taeniosis was 1.2% (95%CI:
0.4–2.9). All five of 404 rES33 positive individuals also
had Ab to CC-Ag or positive Ag-results. Only three (0.7%;
95%CI: 0.4–2.9) participants were positive for the presence
of CC-Ag. The prevalence of TSOL was slightly higher
among those presenting with headaches or seizures (3.7%;
95%CI: 0.8–10.4) than among those without such symp-
toms (2.2%, 95%CI: 0.9–4.4), but this difference was not
statistically significant (Tables 2 and 3).
The district of origin and serological results were avail-
able for 399 out of 433 initially recruited individuals.
The prevalence proportion of TSOL was considerably
higher among participants living in the Mbulu district
(5.2%, 95%CI: 1.9–10.4) than in other districts (0.8%;
95%CI: 0.1–2.8) (Fig. 1), a difference which was statisti-
cally significant (p = 0.008) (Table 1).
Association between CD4+ counts, HIV stages, HAART and
TSOL
There were only four HIV+ participants positive for any
TSOL test. Median CD4+ counts of the four HIV+/TSOL
+ individuals were 358 cells/μl (range 170 to 554) while it
was 399 cells/μl (range 9 to 1 878) among the 166 HIV+
participants of the matched population negative to all
TSOL tests (p = 0.88). Of four HIV+/TSOL+, three indi-
viduals were classified in HIV stage I and one in stage III,
a distribution similar to that found in those with all TSOL
tests negative (p = 0.88). All four HIV+/TSOL+ individuals
had been receiving HAART for 4 years or less (Table 4).
Table 3 Past neurological history, public health and diagnostic
data of HIV+ and HIV– individuals of the matched study
population
Variables HIV+ (170) HIV– (170) Total (340) p-value
n % n % n %
History of acute headaches
Yes 38 22.4 16 9.4 54 15.9 <0.01
History of chronic headaches
Yes 6 3.5 4 2.4 10 2.9 0.52
Past or present epileptic seizures
Yes 4 2.4 3 1.8 7 2.1 0.70
History of psychiatric disorders
Yes 15 8.8 6 3.5 21 6.2 0.04
Current CNS symptoms
Yes 7 4.1 1 0.6 8 2.4 0.03
Current PNS symptoms
Yes 13 7.6 5 2.9 18 5.3 0.05
CC-Ag
Positive 1 0.6 0 0.0 1 0.3 0.32
CC-Ab by LLGP-EITB
Positive 4 2.4 4 2.4 8 2.4 1.00
CC-Ab by rT24H-blot
Positive 4 2.4 4 2.4 8 2.4 1.00
Taeniosis-Ab
Positive 1 0.6 2 1.2 3 0.9 0.56
NCCa
Positive 4 2.4 4 2.4 8 2.4 1.00
History of tapeworm carrier in family
Yes 7 4.1 3 1.8 10 2.9 0.20
Handwashing before eating
Yes 12 7.1 20 11.8 32 9.4 0.14
Anthelmintic treatment in the past year
Yes 12 7.1 25 14.7 37 10.9 0.02
CNS central nervous system, PNS peripheral nervous system, HAART highly
active antiretroviral therapy, CC cysticercosis, Ag antigen, Ab antibody,
LLGP-EITB lentin-lectin glycoprotein electroimmunosorbent blot,
NCC neurocysticercosis
aAccording to the revised diagnostic criteria proposed by Del Brutto [10]
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Radiological and serological results of TSOL+ individuals
among the matched pairs and initially recruited
population
Details on the four HIV+ patients (P1-P4) and the four
HIV– patients (P5-P8) who were also TSOL+ in addition
to two HIV– participants (P9-P10) who could not be
matched but were TSOL+ (initially recruited study popula-
tion; Fig. 2) are provided in Table 4. More clinical details on
these ten patients are shown in Additional file 2: Table S1.
Overall, all four HIV+/TSOL+ and three of four
HIV–/TSOL+ participants of the matched study popula-
tion agreed to have at least one CT scan at the time of
Table 4 Radiological and serological results of TSOL+ individuals of the matched and initially recruited population
P 1 P 2 P 3 P 4 P 5 P 6 P 7 P 8 P 9 P 10
Matched study group yes yes yes yes yes yes yes yes no no
Age 50 46 45 60 46 28 27 51 38 14
Gender f m m m m f f m m m
First clinical examination
HIV parameters
HIV status + + + + - - - - - -
HIV stage I I I III - - - - - -
HAART drugs ZDV/3TC/EFZ ZDV/3TC/EFZ ZDV/3TC/EFZ ZDV/3TC/EFZ - - - - - -
HAART treatment since
(years)
<1 3 3 4 n.a. n.a. n.a. n.a. n.a. n.a.
NCC symptoms/signs - - - headaches - severe headaches - - epi epi, enca
CT diagnosis
Calcified cysts + - + + o o o o + -
Viable cysts - - - - o o o o - +
Other NCC relevant findings - - - - o o o o - hydrocephalus
Laboratory diagnosis
CD4+ counts 554 433 276 170 n.a. n.a. n.a. n.a. n.a. n.a.
CC- Ab + + + + + + + + + +
CC-Ag - - - + - - - - - +
Taeniosis-Ab + - - - - - + + + +
Second clinical examination
NCC symptoms/signs x x - - - severe headaches - x d epi, enca
CT diagnosis x
Calcified cysts x x + + + - + x d +
Viable cysts x x - - - - - x d +
Other NCC relevant
findings
x x - - - hydrocephalusb - x d hydrocephalus
Laboratory findings
CD4+ counts 521 400 368 184 n.a. n.a. n.a. n.a. d n.a.
CC-Ab + + - - + x x x d x
CC-Ag - - - + - x x x d x
Taeniosis-Ab + - - - - x x x d x
Taeniosis-copro-Ag - - - - - - - x d x
P patient number, m male, f female, HIV human immunodeficiency virus, HAART highly active antiretroviral therapy, ZDV zidovudine, 3TC lamivudine, EFZ efavirenz,
NCC neurocysticercosis, epi epilepsy, enc encephalopathy, CT computed tomography, CD4+ CD4+ T-lymphocyte cell counts, n.a. not applicable, because in the
group of HIV– these parameters were not tested and no HAART was taken, CC cysticercosis, Ab antibodies, Ag antigen, + positive, − negative, o was not taken at
once due to ethical concerns of performing a CT scan in healthy individuals, but was offered when the positive test serology was confirmed, x patient refused or
was not found, d patient died before 2nd examination with unclear diagnosis (strong headaches and abdominal pain reported before death)
aPatient was unconscious with signs of brainstem involvement and generalized increased muscle tone leading to flexion contractures of all four limbs, most likely
in the context of increased intracranial pressure
bMass in 4th ventricle causing obstructive hydrocephalus
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their first and second clinical examination. The two un-
matched HIV–/TSOL+ individuals (P9, P10) received a
CT scan at their first clinical examination due to the se-
vere clinical condition they were in (epilepsy, encephal-
opathy). None of the 166 HIV+/TSOL– participants
presented with brain lesions compatible with NCC, but
three (P1, P3 and P4) of the four HIV+/TSOL+ had
definitive NCC. The fourth participant did not show any
lesions in the brain (P2). This would suggest an overall
specificity of 99.4% (95%CI: 96.7–100) of the CC tests
(Ag-ELISA, LLGP-EITB, rT24H-immunoblot) to detect
NCC among the HIV+ patients in this population. There
were too few cases to estimate the sensitivity with any
precision. Overall, there was perfect agreement between
the EITB and rT24H for the detection of Ab to CC
(Tables 3 and 4).
Among the three matched HIV–/TSOL+ participants
with CT scan results, two were found to have definitive
NCC (P5, P7) and one other had probable NCC (P6).
The latter presented with an obstructive hydrocephalus
and a mass in the 4th ventricle. Among all HIV– partici-
pants positive to TSOL and receiving neuroimaging,
four out of five had lesions of NCC, suggesting that, al-
though there were only small numbers, HAART may
not impact on the proportion of NCC among those posi-
tive for CC in people with HIV/AIDS. The proportion of
NCC was therefore 1.8% among the matched HIV+ par-
ticipants, but cannot be estimated in the matched HIV–
participants since only three had a CT scan.
Among the seven NCC cases, five presented with cal-
cified lesions without perilesional edema and were free
of any viable cysts. Among the two unmatched HIV–/
NCC participants, one was found to have multiple viable
cysts in the parenchyma, some of them with perilesional
edema (P10), and the other had several calcified cysts
(P9). The number of detected lesions per NCC case in
this study ranged from one to ten, except in P10, where
more than 20 active lesions could be identified. No
lesions outside the parenchyma were detected (Table 4).
Description of symptoms among patients with NCC
Four (1 HIV+, 3 HIV–) of eight participants with defini-
tive or probable NCC presented with neurological symp-
toms. Two of the symptomatic participants presented
with headaches (1 HIV+ with acute and 1 HIV– with
chronic headaches) and two HIV– individuals with epi-
lepsy. One HIV– participant (P10), a boy aged 14 years,
was unconscious at the time of admission to HLH with
signs of brainstem involvement and generalized in-
creased muscle tone leading to flexion contractures of
all four limbs, most likely in the context of increased
intracranial pressure. P10 was the only participant with
positive serological results for all tests (CC-Ab, CC-Ag
and taeniosis-Ab). The CD4+ counts of the only
symptomatic (presenting with acute headaches) HIV+
individual (P4) was 170 cells/μl, the lowest level of the
four HIV+ individuals who were positive to TSOL
(Table 4).
Follow-up of TSOL+ individuals
Of the ten participants found positive to TSOL at base-
line, three were lost to follow-up, including one un-
matched HIV– participant who died for unclear reasons
(strong headaches and abdominal pain reported before
death). Five (4 HIV+ and 1 HIV–) of the seven followed
participants provided sera and six (4 HIV+ and 2 HIV–)
provided a stool sample. Seven (4 HIV+ and 3 HIV–)
participants had a stool examination at the time of fol-
low up, but all of them had a negative copro-Ag-ELISA
test result. The only HIV+ participant positive to rES33
at baseline was still positive at follow-up. Among the five
participants positive to CC at baseline, one HIV+ partici-
pant became sero-negative to the tests detecting Ab.
Interestingly, this participant (P3) had an increase of
92 cells/μl in CD4+ (from 276 to 368 cells/μl; increase of
33% from baseline), in contrast to the three other HIV+
participants for whom the CD4+ counts decreased slightly
or remained similar. Only three participants accepted to
undergo a second CT examination. Two of them did not
show any changes, whereas P10, who had shown several
viable cysts on the first CT scan, revealed mostly calcifica-
tions as well as a few viable cysts. This young (14-year-
old) patient was hospitalized and, after serological and
radiological confirmation, received anti-inflammatory
(dexamethasone) and anthelminthic (albendazole, niclosa-
mide) treatments repeatedly during the whole study
period. There were no major improvements in the symp-
toms after treatment and the patient was transferred to a
home for children with special needs after the study.
Overall, there was no change in the clinical presentation
of all the TSOL+ individuals at follow-up. None of the
asymptomatic NCC cases reported new clinical signs/
symptoms (Table 4, Additional file 2: Table S1).
Discussion
TSOL has only been investigated patchily with contradict-
ory results in people living with HIV/AIDS and the impact
of CD4+ counts, HAART duration and HIV stages on the
incidence of T. solium and the exacerbation of NCC have
not been explored so far. Depending on the endemicity of
TSOL, between 10 and 20% of HIV+ individuals may also
present with TSOL and/or suffer from NCC, but there are
currently no recommendations for adequate case manage-
ment in cases of co-infection [31]. This important gap for
controlling TSOL/NCC has largely been overlooked. Our
study matched HIV+ to HIV– participants by age, gender
and village of residence to adjust for potential environ-
mental contamination with eggs of T. solium and the
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varying immunological response in relation to age and gen-
der. To our knowledge, our study is the first to adjust for
such factors in people living with HIV/AIDS and was de-
signed to address these knowledge gaps. Unfortunately, the
prevalence of taeniosis, CC and NCC was a lot lower than
had been reported in the region by past studies [9, 17], and
limited our ability to fully explore these questions with
confidence.
We found a prevalence proportion of Ab to CC of 2.4%
among the matched participants and of 2.5% in the ini-
tially recruited population, with no major differences be-
tween the HIV+ and HIV– participants. These prevalence
rates of Ab to CC were similar to a 2.2% prevalence rate
reported among healthy individuals in Kenya [50]. How-
ever, our estimate is much lower than that found in a
study conducted at the same time in communities of the
Mbulu district where a prevalence proportion of 16.3%
was reported when using a commercially available West-
ern blot test (LDBIO Diagnostics) [51]. When using data
from all participants initially recruited, the prevalence of
TSOL was highest in the Mbulu district (5.2%), and this
was true among HIV+ and HIV– participants, but was still
lower than that found by Mwang’onde et al. [51]. Possible
explanation for these differences are the use of a different
diagnostic test for the detection of Ab, possible selection
bias of participants as no details on sampling is provided
by the authors of a previous study [51], and possible clus-
tering of CC in certain villages within the Mbulu district
which was already described by Ngowi at al. [52]. Cluster-
ing of CC by villages in Africa has also been observed in
pigs in the Mbulu district and in humans living in other
countries [16, 52].
The prevalence of CC-Ag positive individuals in our
study is also considerably lower than that found in other
countries of southeastern Africa: Zambia (5.8%), Tanzania
(16.7%), and the Democratic Republic of Congo (21.6%)
[15–17, 53], and was lower than the overall prevalence of
7.3% for Africa presented in [54]. However, a study from
Burkina Faso recorded varying proportions, from 0.0
to 11.5% in 60 villages, which partially supports our
findings [55].
In our study, NCC was confirmed by serology and CT
scan in about 2% of HIV+. In a study conducted in
India, of 100 HIV+ serum samples two (2%) were de-
tected with CC-Ab by EITB [56]. In Mexico, only 1.1%
of NCC have been reported in a study among HIV/AIDS
cases, compared with 2.4% in control autopsies [33].
Furthermore, a study conducted in Mozambique found
a CC-Ab proportion of 10.2% in 601 HIV+ individuals
by a commercial multiplex Western Blot IgG test for
several parasites (LDBIO Diagnostics) [31].
Overall, it has to be considered that due to the
matched design in this study and no use of a cross-
sectional approach, obtained prevalence estimates have
to be interpreted carefully. No cluster analysis could be
performed for this reason too.
Four TSOL individuals, two matched individuals (1
HIV+, 1 HIV–) as well as two initially recruited individ-
uals (2 HIV–) presented with neurological symptoms.
Our results are limited by the fact that symptomatic
NCC cases with a negative CC-Ab and CC-Ag titer and
people with extraparenchymal or spinal lesions might have
been missed. Ethical restrictions did not allow for further
radiological follow-up of sero-negative HIV– participants
and funds as well as logistics made the performance of
magnetic resonance imaging (MRI) impossible.
Of all eight NCC cases identified in our wider study
population four were classified as asymptomatic and
four as symptomatic NCC cases. This correlates with
findings of other studies that proposed that around 50%
of NCC cases remain asymptomatic [4, 56]. The two re-
ported neurological symptoms/signs were headaches and
epilepsy, which is consistent with the main neurological
presentations of NCC [2–4]. All asymptomatic NCC
cases showed one to five intraparenchymal calcified le-
sions in the CT scan, and none of those followed up de-
veloped neurological symptoms 8 to 10 months later.
This does not rule out that these individuals may be-
come symptomatic in the future.
The prevalence of taeniosis-Ab in the initially re-
cruited population was 1.2%, the first such estimate for
northern Tanzania. However, this population is not rep-
resentative of the community but was selected to match
residence of HIV+ individuals receiving care at the
HLH. Data on taeniosis-Ab are still scarce worldwide,
mostly due to the unavailability of a commercial diag-
nostic test [57]. The rES33-immunoblot in-house assay
has been reported to have a sensitivity of 98% and a spe-
cificity of 99% for the detection of the adult stage of T.
solium in human intestines [45]. However, the presence
of taeniosis-Ab only reflects exposure to the adult tape-
worm and cannot differentiate past from present infec-
tions. Previous estimates of the prevalence of adult
tapeworm infections measured with a copro-Ag-ELISA
in endemic areas vary from 0.1 to 4.0% in community-
based settings, with only one study from Zambia report-
ing a prevalence of 11.9% [13, 15–18]. In our study, all
individuals with a positive taeniosis-Ab titer lived in the
Mbulu district (Fig. 1). In addition to the possible nat-
ural clustering of TSOL, in contrast to the other dis-
tricts, Mbulu had only recently started annual mass drug
administration (MDA) of anthelminthic drugs which
may have reduced the natural taeniosis prevalence.
Our analysis of factors for TSOL infection revealed
that the HIV+ group reported washing their hands less
often, was more exposed to people with taeniosis in their
household but had taken fewer anthelminthic drugs in
the past (as specifically prescribed treatment or in mass
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drug administration initiatives). However, they also con-
sumed less pork (Tables 2 and 3), so there could be a
slight tendency that the HIV+ group may be slightly
greater at risk of CC and a little less to taeniosis, based
on known infection routes [2–4]. However, serological
findings of our study could not support this hypothesis
as in our study four HIV– individuals had a positive
taeniosis-Ab titer in comparison to only one HIV+
individual.
In the present study, we could not detect any differ-
ence in the prevalence of taeniosis, CC and NCC be-
tween matched HIV+ and HIV– individuals. Our results
are in accordance with that of Walson et al., who sug-
gested that helminth prevalence in HIV+ individuals is
similar to the general population prevalence in endemic
settings [58], although others have found intestinal
helminths - like Strongyloides stercoralis - to be more
prevalent in HIV+ people [59, 60]. However, a clear
drawback of our study was the seemingly low prevalence
of TSOL in our overall study population and therefore
differences between the HIV+ and HIV– individuals
may have gone unnoticed. Furthermore, there was no
difference in the presence of CC-Ab between matched
HIV+ and HIV– individuals. A reduced production of
Ab against protozoans such as Toxoplasma gondii has
been discussed in HIV+ individuals, as well as the pos-
sible failure of serological diagnostic tests to detect these
co-infections in severely immunocompromised individ-
uals [61]. In our study, CC-Ab positive HIV+ individuals
had moderately reduced to normal CD4+ counts and
were probably still immunocompetent enough to pro-
duce Ab. CC in HIV+ individuals, including Ab and/or
Ag-positive individuals, was distributed equally (1/4) in
the four groups of individuals with defined CD4+ counts
(group I: ≤200; group II: 201-350; group III: 351-500;
group III: >500). Therefore, CC did not seem to be asso-
ciated with CD4+ counts in our study.
The single HIV+/NCC case with neurological symp-
toms presented with acute headaches, calcified cysts,
CD4+ counts of 170 cells/μl and was HIV stage III. All
asymptomatic HIV+/NCC cases were HIV stage III. This
result is in agreement with previous studies reporting
symptomatic HIV+/NCC cases in individuals with CD4+
counts <250 cells/μl [27, 32]. However, acute headaches
in this case might also be linked to HIV infection,
HAART, or reasons other than NCC.
Our results showing the absence of viable cysts or
perilesional edemas lesions among HIV+/NCC cases are
in contrast with a review of 27 HIV+/NCC cases with
multiple parenchymal active lesions (viable cysts and en-
hancing lesions) as the most frequent radiological find-
ings [32]. Beside genetic aspects, of the host and/or the
parasite, and lower infection pressure the prevailing of
cerebral calcifications in our HIV+ study population on
the one hand may point towards a still functional im-
mune system that is able to eliminate the parasite and
on the other hand may be due to low infection pressure.
Another reason might be that the HIV+/NCC cases ac-
quired HIV after contracting TSOL.
Although this study was designed to allow similar
levels of exposure to T. solium eggs in the HIV+ and
HIV– groups, it had some important limitations which
should be noted. First, the very small number of TSOL+
individuals in both the HIV+ and HIV– groups meant
that we had very limited statistical power to identify any
differences. Such result was surprising given that en-
demic levels of CC/NCC were recently reported in the
same study area [9, 51].
Second, the vast majority of the HIV+ participants
were receiving HAART, meaning that the impact of
compromised immunological response usually associated
with HIV on taeniosis, CC or NCC was diluted. An add-
itional HIV+/HAART– group would have provided
more detailed information on a possible influence of
HAART (or the initiation of it) on the prevalence of
T/CC/NCC and its clinical characteristics. However, re-
cruitment of a sufficient number of HIV+ people that do
not receive HAART was not possible within the study
period due to national ethical reasons. So far, severe pro-
gressive and fatal NCC cases in HIV+ individuals were
mostly described in patients who were not receiving
HAART [7, 62, 63]. However, a recent cross-sectional
study of a group of 601 HIV+ individuals conducted in
Mozambique could not detect a difference in the presence
of CC-Ab between HIV+ patients who were taking
HAART and those who were not, nor was there a correl-
ation between HAART duration and CC-Ab titers [31].
Conclusions
In conclusion, we did not detect any difference in preva-
lence and manifestation of taeniosis, CC and NCC be-
tween matched HIV+ and HIV– individuals in a TSOL
endemic area of northern Tanzania. However, the herein
presented data on TSOL/HIV co-infection obtained in a
comparative study design are the first of its kind. This
study clearly points out that further large-scale studies
are urgently required to re-examine TSOL infection in
HIV+ individuals and in patients who are and are not
on HAART, as well as NCC progression in HIV+
individuals.
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